|
[1] 陈路.强直性脊柱炎胸腰椎后凸畸形合并髋关节强直的临床治疗研究[D].南昌大学,2021.
[2] 刘扬,沈逸,朱琦,等.强直性脊柱炎寒热证型超声下外周附着点炎表现的差异研究[J].现代中西医结合杂志,2022,31(9):1175-1181,1314.
[3] 张腾飞,岳宗进,张璐璐.葛根素抑制强直性脊柱炎患者成纤维细胞的增殖和成骨分化[J].西安交通大学学报(医学版),2020,41(2):294-298.
[4] Zhenhua L, Mingxi C, Haoteng K, et al. Fibroblast insights into the pathogenesis of ankylosing
spondylitis[J].J Inflamm Res, 2023,16:6301-6317.
[5] Zeng Y, He R, Liu Y, et al. HDAC1 regulates
inflammation and osteogenic differentiation of ankylosing spondylitis
fibroblasts through the Wnt-Smad signaling pathway[J].J Orthop Surg Res, 2022,17(1):343-343.
[6] Knights AJ,Farrell EC,Ellis OM, et al. Synovial fibroblasts assume distinct functional identities
and secrete R-spondin 2 in osteoarthritis.[J].Ann Rheum Dis, 2022,82(2):272-282.
[7] Wei Y, Zhang S, Shao F, et al. Ankylosing spondylitis: from pathogenesis to
therapy[J].Int Immunopharmacol, 2025, 145:113709.
[8] 胡剑威,丁超,吴莹,等.青藤碱及其制剂治疗类风湿性关节炎的研究进展[J].陕西中医药大学学报,2024,47(3):1-7.
[9] 李晨曦,王汉伟.正清风痛宁联合阿达木单抗对类风湿性关节炎临床症状及炎性因子的改善效果分析[J].世界复合医学,2023,9(4):134-136,144.
[10] 李涛,张海勇,史守禄,等.正清风痛宁联合阿司匹林治疗强直性脊柱炎的效果[J].中国药物滥用防治杂志, 2024, 30(1): 155-159.
[11] 唐琳,陆晓珊,林也,等.正清风痛宁联合应用治疗IgA肾病有效性和安全性的Meta分析[J].时珍国医国药, 2020, 31(12): 3050-3054.
[12] 万翠红,王积义,魏从孝,等.正清风痛宁联合四妙汤加减治疗痛风性关节炎的疗效[J].江苏医药,2023,49(7):727-730.
[13] 谢慧聪.正清风痛宁辅治活动期类风湿关节炎临床观察[J].实用中医药杂志,2023,39(7):1354-1356.
[14] 柯淑芳,石文利.盐酸青藤碱肠溶片联合美洛昔康、甲氨蝶呤治疗类风湿关节炎效果评价[J].中外医学研究, 2020, 18(11): 40-42.
[15] 姚茹冰,彭浩,蔡孟成,等.基于网络药理学的青风藤治疗类风湿关节炎的作用机制研究[J].药学实践杂志, 2021, 39(1): 17-22.
[16] Zeling H, Xiao M, Junming C, et al. Sinomenine hydrochloride injection for knee osteoarthritis: a protocol for systematic review and meta-analysis[J].Medicine, 2022,101(2):e28503.
[171] Wang J ,Lou W ,Li Y , et al.Progress in
targeted therapy for ankylosing spondylitis: a
review.[J].Medicine,2024,103(48):e40742.
[18] 丁香,刘健,陈晓露,等.雷公藤甲素通过miR-23a-3p/PTEN/PI3K/AKT/mTOR改善强直性脊柱炎滑膜成纤维细胞作用机制[J].中华中医药杂志, 2023, 38(12): 6024-6029.
[19] Yuening C, Zhaoyi L, Qing Y, et al. Integrating network pharmacology and experimental
verification to explore the mechanism of Tripterygium wilfordii in ankylosing
spondylitis[J].Medicine,2023,102(50):e36580.
[20] Xu H, Juqi Z, Mingli G, et al. Identification of potential ferroptosis-associated biomarkers in rheumatoid arthritis [J].Front Immunol,2023,14:1197275.
[21] Deng W, Zhang W, He Q. Study on the
mechanism of puerarin against osteoarthritis from ferroptosis based on network
pharmacology and bioinformatics[J].Naunyn Schmiedebergs Arch Pharmacol, 2023,397(2):959-968.
[22] 郭磊,牛啸博.骨性关节炎药物治疗的研究进展[J].内蒙古医学杂志,2022,54(8):934-937.
[23] Augusta O, Casper W, Alexandre S, et al. Efficacy and safety of non-pharmacological and non-biological
interventions: a systematic literature review informing the
2022 update of the ASAS/EULAR recommendations for the management of axial
spondyloarthritis[J].Ann Rheum Dis, 2023,82(1):142-152.
[24] Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective[J].Biochem Pharmacol, 2020,180:114147.
[25] 罗艳群,沈小兰,蔡三金,等.青风藤化学成分和药理作用的研究进展及其质量标志物(Q-Marker)的预测分析[J].中草药,2022,53(3):898-911.
[26] 王玺,张智勇,仇萍,等.青风藤、青藤碱及其相关制剂的研究进展[J].中国药学杂志, 2021, 56(2): 85-93.
[27] Li JM, Yao YD, Luo JX, et al. Pharmacological mechanisms of sinomenine in anti-inflammatory immunity and osteoprotection in rheumatoid arthritis: a systematic review[J].Phytomedicine, 2023,121:155114.
[28] 贾梦雪,朱静平,王振兴,等.青风藤化学成分、药理和临床应用研究进展[J].中华中医药学刊,2024,17(5):1-17.
|